tanshinone ii a has been researched along with nutlin-3a in 1 studies
| Studies (tanshinone ii a) | Trials (tanshinone ii a) | Recent Studies (post-2010) (tanshinone ii a) | Studies (nutlin-3a) | Trials (nutlin-3a) | Recent Studies (post-2010) (nutlin-3a) |
|---|---|---|---|---|---|
| 61 | 0 | 41 | 698 | 1 | 504 |
| Protein | Taxonomy | tanshinone ii a (IC50) | nutlin-3a (IC50) |
|---|---|---|---|
| Protein Mdm4 | Homo sapiens (human) | 4.6273 | |
| Cellular tumor antigen p53 | Homo sapiens (human) | 1.0388 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.07 | |
| E3 ubiquitin-protein ligase Mdm2 | Homo sapiens (human) | 0.1832 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gong, YP; Guo, Y; Huang, XO; Li, Y; Ma, HB; Wang, FF; Xiang, B | 1 |
1 other study(ies) available for tanshinone ii a and nutlin-3a
| Article | Year |
|---|---|
The combination of Nutlin-3 and Tanshinone IIA promotes synergistic cytotoxicity in acute leukemic cells expressing wild-type p53 by co-regulating MDM2-P53 and the AKT/mTOR pathway.
Topics: Acute Disease; Adolescent; Adult; Aged, 80 and over; Benzofurans; Cytotoxins; Drug Synergism; Female; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Imidazoles; Leukemia; Male; Middle Aged; Piperazines; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-mdm2; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53 | 2019 |